1
|
Basquiera AL, García MJ, Martinez Rolón J, Olmedo J, Laviano J, Burgos R, Caeiro G, Remaggi G, Raña P, Paoletti M, González CM, Fernández I, Pavlovsky A, Perusini MA, Rodriguez A, Guanchiale L, Carvani A, Mandrile L, Figueroa F, Vicente Reparaz A, Fragapane Mathus PN, Garate G, Fauque ME, Kantor G, Cruset S, Gonzalez Lorch JS, Szelagowski M, Giarini MP, Oliveira N, García MC, Ventriglia MV, Pereyra PH, Gutierrez DR, Kusminsky G, Troccoli J, Freitas MJ, Cranco S, Del V Sanchez N, Rey I, Funes ME, Jarchum S, Freue J, Miroli A, Guerrero O, López Ares L, Campestri R, Bove V, Salinas GN, Cabrejo M, Milone JH, Zabaljauregui S, Gotta D, Dupont JC, Stemmelin G. Clinical characteristics and evolution of hematological patients and COVID-19 in Argentina: a report from the Argentine Society of Hematology. Medicina (B Aires) 2021; 81:536-545. [PMID: 34453794] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/13/2023] Open
Abstract
Individuals with malignancies and COVID-19 have a lower survival compared with the general population. However, the information about the impact of COVID-19 on the whole hematological population is scarce. We aimed to describe the 30th day overall survival (OS) after COVID-19 infection in patients with a hematological disease in Argentina. A completely anonymous survey from the Argentine Society of Hematology was delivered to all the hematologists in Argentina; it started in April 2020. A cut-off to analyze the data was performed in December 2020 and, finally, 419 patients were reported and suitable for the analysis (average age: 58 years, 90% with malignant diseases). After the COVID-19 diagnosis, the 30-day OS for the whole population was 80.2%. From the entire group (419), 101 (24.1%) individuals required intensive care unit admission, where the 30-day OS was 46.6%. Among allogeneic stem cell transplant recipients, the 30-day OS was 70.3%. Factors associated with a low OS were two or more comorbidities, an active hematological disease and history of chemotherapy. In individuals with the three factors, the 30-day OS was 49.6% while the 30-day OS in those without those factors was 100%. Patients with hematological diseases have a higher mortality than the general population. This group represents a challenge and requires careful decision-making of the treatment in order not to compromise the chances of cure.
Collapse
Affiliation(s)
- Ana L Basquiera
- Hospital Privado Universitario de Córdoba, Córdoba, Argentina. E-mail:
| | - Mercedes J García
- Hospital Privado Universitario de Córdoba, Córdoba, Argentina
- Hospital Raúl Ferreyra, Córdoba, Argentina
| | | | | | | | - Rubén Burgos
- Conciencia-Instituto Oncohematológico de la Patagonia, Argentina
| | - Gastón Caeiro
- Hospital Privado Universitario de Córdoba, Córdoba, Argentina
- Hospital Raúl Ferreyra, Córdoba, Argentina
| | | | - Pablo Raña
- Conciencia-Instituto Oncohematológico de la Patagonia, Argentina
| | | | | | | | | | | | | | | | - Analia Carvani
- Hospital Diego Paroissien, Isidro Casanova, Buenos Aires, Argentina
| | - Laura Mandrile
- Hospital Diego Paroissien, Isidro Casanova, Buenos Aires, Argentina
| | | | | | | | | | | | | | - Soledad Cruset
- Hospital El Cruce, Florencio Varela, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | | | | | | | - María J Freitas
- Hospital Nacional Posadas, El Palomar, Buenos Aires, Argentina
| | | | | | - Irene Rey
- Hospital Ramos Mejía, Buenos Aires, Argentina
| | | | | | | | | | | | | | | | - Victor Bove
- Instituto Oncohematológico Privado, Río Cuarto, Córdoba, Argentina
| | | | - María Cabrejo
- Sanatorio Municipal Julio Méndez, Buenos Aires, Argentina
| | | | | | - Daniel Gotta
- Hospital Urquiza, Concepción del Uruguay, Entre Ríos, Argentina
| | | | | |
Collapse
|